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Nod2, a member of the Apaf1/Nod protein family, con-
fers responsiveness to bacterial products and activates
NF-B, a transcription factor that plays a central role in
innate immunity. Recently, genetic variation in Nod2
has been associated with susceptibility to Crohn’s dis-
ease. Here, we report that expression of Nod2 is induced
upon differentiation of CD34 hematopoietic progenitor
cells into granulocyte or monocyte/macrophages. In pe-
ripheral blood cells, the highest levels of Nod2 were
observed in CD14 (monocytes), CD15 (granulocytes),
and CD40/CD86 (dendritic cells) cell populations. No-
tably, stimulation of myeloblastic and epithelial cells
with bacterial lipopolysaccharide or TNF resulted in
up-regulation of Nod2. A search for consensus sites
within the Nod2 promoter revealed a NF-B binding
element that was required for transcriptional activity in
response to TNF. Moreover, ectopic expression of p65
induced transactivation, whereas that of dominant-neg-
ative IB blocked the transcriptional activity of the
Nod2 promoter. Upon stimulation with TNF or lipopo-
lysaccharide, both p50 and p65 subunits of NF-B were
bound to the Nod2 promoter. Thus, Nod2 expression is
enhanced by proinflammatory cytokines and bacterial
components via NF-B, a mechanism that may contrib-
ute to the amplification of the innate immune response
and susceptibility to inflammatory disease.
Innate immunity recognizes invading microbes and triggers
a host defense response aimed to the clearance of the invading
pathogens. Studies of the host defense system in Drosophila
revealed that Toll receptors play an important role in combat-
ing the invasion of pathogens (1). At least ten homologues of
Drosophila Toll-like receptors (TLRs)1 have been identified in
mammals and shown to participate in the recognition of micro-
bial components and activation of innate immunity, which
leads to the development of antigen-specific immune responses
(2, 3). Each membrane-associated TLR recognizes specific pat-
terns of microbial components (i.e. TLR2 is responsible for the
recognition of certain lipoproteins, whereas TLR4 recognizes
lipopolysaccharides) (4, 5). TLRs are composed of a cytoplasmic
Toll/interleukin-1 receptor domain and extracellular leucine-
rich repeats (LRRs) (6). Nods are members of another family of
proteins that have been implicated in the intracellular recog-
nition of pathogen components (7). Nod1 and Nod2, the first
members of the family to be identified, are composed of an
N-terminal caspase recruitment domain, a centrally located
nucleotide binding oligomerization domain, and C-terminal
LRRs (7). Nod proteins have been shown to recognize bacterial
components including bacterial lipopolysaccharides (LPS)
and/or peptidoglycan through their LRRs, and this interaction
leads to the activation of NF-B, a transcription factor that
plays a central role in innate immunity (7, 8). Studies using
genetically modified cells have revealed that Nod1 and Nod2
activate NF-B by means of the serine/threonine kinase RICK/
Rip2 (9). Recently, a frameshift mutation and two nucleotide
polymorphisms in the coding region of Nod2 have been associ-
ated with susceptibility to Crohn’s disease, a chronic inflam-
matory disorder of the intestinal tract (10–12). The frameshift
mutation results in a truncated Nod2 that is deficient in induc-
ing LPS-mediated NF-B activation (10). In addition, missense
mutations in the region encoding the nucleotide binding oli-
gomerization domain of Nod2 have been associated with sus-
ceptibility to Blau syndrome, another granulomatous inflam-
matory disorder (13).
Previous studies showed that Nod1 is broadly expressed in
tissues (14), while the expression of Nod2 seems to be more
restricted to monocytes (15). Here we report that Nod2 is ex-
pressed in monocytes, granulocytes, and dendritic cells and to
a lesser extent in T lymphocytes. Significantly, Nod2 levels are
up-regulated in myelomonocytic and epithelial cells upon stim-
ulation with TNF or LPS. Furthermore, we demonstrate that
induction of Nod2 by TNF or LPS is mediated transcription-
ally through NF-B. We suggest that transcriptional regula-
tion of Nod2 by bacterial components and proinflammatory
cytokines may play a role in innate immune responses and
contribute to susceptibility to inflammatory disease.
EXPERIMENTAL PROCEDURES
Cell Lines—Human leukemia cell lines HL-60, U937, THP-1, K562,
and Jurkat and breast cancer cell lines MCF-7 and MDA-MB231 were
maintained in RPMI 1640 medium (Seromed Biochrom KG, Berlin,
Germany) supplemented with 10% fetal calf serum (FCS) (Flow Labo-
ratories, Irvine, CA). HEK293T cells were grown in Iscove’s modified
Dulbecco’s medium (Invitrogen) supplemented with 10% FCS. Leuke-
mic Mo7e cells were cultured in Iscove’s modified Dulbecco’s medium-
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10% FCS with 5 ng/ml of recombinant human IL-3 (Immunex, Seattle,
WA). Breast cancer MDA-MB435 and SUM159 cell lines were cultured
as described elsewhere (16, 17). Normal colon FHC cells were grown in
DMEM/HAM’S F-12 with 10% FCS, 10 ng/ml cholera toxin, 5 g/ml
transferrin, 5 g/ml insulin, and 100 ng/ml hydrocortisone (Sigma).
Primary Cells—Peripheral blood progenitors were obtained from nor-
mal donors undergoing mobilization for allogeneic progenitor cell trans-
plantation. All donors signed informed consent according to Guidelines
from the Committee for the Protection of Human Subjects at the Uni-
versity of Navarra. CD34 cells were selected from the peripheral blood
mononuclear cell population and induced to undergo granulocyte or
monocyte/macrophage differentiation as previously described (18). At
the indicated time points, cells were collected for mRNA expression and
flow cytometric analysis. Dendritic cells were generated from periph-
eral blood monocytes and analyzed by flow cytometry as described
elsewhere (19).
Gene Reporter Assays—Genomic PCR fragments of 3 kb and 527 bp
from the promoter region of Nod2 (Nod2pt), starting 121 bases up-
stream from the initiation codon, were cloned into XhoI and HindIII
sites of the pGL2-basic luciferase reporter vector (Promega). pEF1-
BOS--gal and pcDNA3-FLAG-DC-CIITA were described previously
(15, 20). pYGFP-p65 was a gift of Johannes Schmid (University of
Vienna). Expression plasmids to produce NF-AT4, NF-IL3, NF-IL6,
cAMP-response element-binding protein, and Elk in pCMV-SPORT6
were obtained from Research Genetics. pcDNA3-p53 and pCMV-c-Myc
were a gift of Michael Clarke (University of Michigan).
pcDNA3-FLAG-IRF7 and GATA-1 were obtained from David Levy
(New York University) and Vishva Dixit (Genentech), respectively.
HEK293T cells were cotransfected with 1 g of pGL2-Nod2pt (527-bp
promoter fragment) and 50 ng of pEF1-BOS--gal in triplicate by using
FuGENE 6 reagent (Roche Molecular Biochemicals) or with 166 ng of
expression plasmid of each transcription factor indicated in Fig. 5C, 100
ng of pGL2-Nod2 (3-kb promoter fragment) and 73 ng of pEF1BOS--
gal as previously described (15). When indicated, cells were cotrans-
fected with pGL2-Nod2pt and 1 g of a vector containing a mutated
form of IB that inhibits activation of NF-B (Clontech, Palo Alto, CA).
24 h posttransfection, cells were incubated with 1 g/ml TNF (Sigma)
for 6 h, and then cell extracts were prepared and analyzed for the
relative luciferase activity by a reporter gene assay system (Applied
Biosystems, Foster City, CA). Results were normalized for transfection
efficiency with values obtained with pEF1BOS--gal. Site-directed mu-
tagenesis of the pGL2-Nod2pt vector, containing the 527-bp fragment of
the Nod2 promoter, was carried out by using the QuikChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA) with the following
primers: 5-CCTTTGTGAATTTCCCTT3- and 5-AAGGGAAATTCA-
CAAAGG-3. The Nod2pt DNA insert was sequenced to verify the
mutation.
Reverse Transcriptase (RT)-PCR Analysis—Total RNA was prepared
using TRIZOL reagent (Invitrogen). To assess mRNA expression, a
semiquantitative RT-PCR method was used as previously described
(21). The generated cDNA was amplified by using primers for human
Nod2 (5-AGCCATTGTCAGGAGGCTC-3 in exon 2, and 5-CGTCTC-
TGCTCCATCATAGG-3 in exon 4), IL-1 (5-AAACAGATGAAGTGC-
TCCTTCCAGG-3 and 5-TGGAGAACACCACTTGTTGCTCCA-3),
c-IAP1 (5-TGAGCATGCAGACACATGC-3 and 5-TGACGGATGAAC-
TCCTGTCC-3), c-IAP2 (5-CAGAATTGGCAAGAGCTGG-3 and 5-C-
ACTTGCAAGCTGCTCAGG-3), TRAIL (5-TGATCTTCACAGTGCTC-
CTGC-3 and 5-TGTTGCTTCTTCCTCTGGTCC-3), and glycerald-
ehyde-3-phosphate-dehydrogenase (GAPDH) (21). After 20 (GAPDH),
25 (IL-1), 28 (c-IAP1, c-IAP2, TRAIL), or 30 (Nod2) amplification
cycles, the expected PCR products were size fractionated onto a 2%
agarose gel and stained with ethidium bromide. The Nod2 fragment
was sequenced to verify the authenticity of the PCR product. Quanti-
tative real-time PCR was performed in a 7000 Sequence Detection
System (Applied-Biosystems). The ratio of the abundance of Nod2 tran-
scripts to that of GAPDH transcripts was calculated as 2n, where n is
the CT (threshold cycle) value of GAPDH minus the CT value of Nod2,
and normalized by the value of the sample with the lowest expression
level of Nod2. Specificity of the desired PCR products was determined
by melting curve analysis.
Electrophoretic Mobility Shift Assay—HL-60 cells were cultured for
1 h with 10 ng/ml TNF or 1 g/ml of LPS from Salmonella typhi-
murium (Sigma) in the presence or absence of 1 M Bay11–7082 (Cal-
biochem, La Jolla, CA), an irreversible inhibitor of NF-B activation
(22). Then cells were lysed, and nuclear fractions were resuspended in
20 mM HEPES, pH 7.9, 420 mM NaCl, 1 mM EDTA, 1 mM EGTA, and
20% glycerol. Nuclear extracts (5 g of total protein) were incubated
with a 32P-labeled double-stranded DNA probe from the promoter re-
gion of the Nod2 gene (5-CCTTTGGGAATTTCCCTT-3). Samples were
run on a 5% non-denaturing polyacrylamide gel, in 200 mM Tris borate,
FIG. 1. Analysis of Nod2 mRNA in hematopoietic cell lines.
Total RNA from myelomonocytic (U937, THP-1, K562), megakaryoblas-
tic (Mo7e), and lymphoblastic (Jurkat) cell lines was obtained and
analyzed for Nod2 mRNA levels by semi-quantitative RT-PCR (A) and
real-time PCR (B). Breast cancer epithelial cells (MB435, MB231) were
also analyzed as controls. GAPDH mRNA was used as an amplification
control. Histograms represent the means  S.D. of triplicate analyses.
FIG. 2. Analysis of Nod2 mRNA in
primary hematopoietic cells. Total
RNA was purified from CD34 cells cul-
tured in the presence of M-CSF or G-CSF
(A, B), and immune-purified peripheral
blood cell populations (C, D), and sub-
jected to semiquantitative RT-PCR (A, C)
or real-time PCR (C, D) analysis. GAPDH
mRNA was used as an amplification con-
trol. Histograms represent the means 
S.D. of triplicate analyses.
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2 mM EDTA. Gels were dried and visualized by autoradiography. Su-
pershifts were performed using rabbit polyclonal antibodies specific for
p50 and p65 NF-B family members (Santa Cruz Biotechnology, Santa
Cruz, CA).
RESULTS
Nod2 Is Expressed in Mature Myelomonocytic and Dendritic
Cells—Initial studies showed that Nod2 was expressed primar-
ily in monocytes (15). Consistent with this finding we found
that monoblastic U937 cells and the more mature monocyte-
like cell line THP-1 expressed Nod2 as assessed by semiquan-
titative RT-PCR analysis (Fig. 1A). The levels of Nod2 mRNA
in THP-1 were about 12-fold higher than in U937 cells as
determined by real-time PCR (Fig. 1B). In contrast, undiffer-
entiated myeloblastic K562 cells, megakaryoblastic Mo7e cells,
lymphoblastic Jurkat cells, and two breast cancer cell lines
(MB435, MB231) were all negative (Fig. 1, A and B). To trans-
late these findings to a more physiologically relevant model, we
purified CD34 progenitor cells from peripheral blood, and the
selected population was cultured with either G-CSF or M-CSF
to induce granulocyte or monocyte/macrophage maturation, as
previously described (18). The granulocytic cell population
(CD34 CD15) increased to more than 85% after 20 days of
culture, and showed morphologic features of mature granulo-
cytes.2 When the cells were cultured in the presence of M-CSF,
a clear pattern of monocyte/macrophage maturation was ob-
served, and by day 20 the majority of cells were mature mono-
cytes/macrophages as determined by morphology and immuno-
phenotype (83% of the cells were CD34 CD14). We then
analyzed the levels of Nod2 mRNA in these cell populations
and found that CD34 progenitors expressed low levels of
Nod2, which increased 3- to 5-fold by day 10 and 17- to 20-fold
by day 20 of culture in both monocytic and granulocytic lin-
eages (Fig. 2, A and B). Thus, Nod2 is up-regulated during
myelomonocytic differentiation. Then we analyzed the expres-
sion of Nod2 in peripheral blood populations of B cells (91.4%
CD19 cells), T cells (99.0% CD3 cells), granulocytes (84.0%
CD15 cells), monocytes (99% CD14 cells), and monocyte-
derived dendritic cells (81.1% CD40/CD86 cells). The mRNA
analysis showed that B lymphocytes expressed undetectable
and T cells low levels of Nod2, whereas granulocytes, mono-
cytes, and dendritic cells expressed about 42-, 26-, and 19-fold
more Nod2 mRNA than T-cells, respectively, as determined by
semiquantitative RT-PCR and real-time PCR analyses (Fig. 2,
C and D). Thus, within the hematopoietic system, myelomono-
cytic and dendritic cells express the highest levels of Nod2.
Nod2 mRNA Is Induced in Hematopoietic and Epithelial Cell
Lines by Lypopolysacharide and Tumor Necrosis Factor—It has
been described that Nod2 activates NF-B (15), a transcrip-
tional factor involved in the induction of inflammatory re-
2 O. Gutierrez, F. Prosper, and J. L. Fernandez-Luna, unpublished
results.
FIG. 3. Induction of Nod2 mRNA in HL-60 cells treated with
TNF and LPS. A, myeloblastic HL-60 cells were cultured with LPS or
TNF for the indicated time intervals, and then total RNA was ex-
tracted and analyzed for the expression of Nod2 and IL-1 by semi-
quantitative RT-PCR. B, real-time PCR analysis of HL-60 cells treated
for 24 h with LPS and TNF. GAPDH mRNA was used as an amplifi-
cation control. Histograms represent the means  S.D. of triplicate
analyses.
FIG. 4. Induction of Nod2 mRNA in epithelial cells treated
with TNF. Epithelial cells derived from breast cancer (SUM159,
MCF-7) and normal colon (FHC) were cultured with TNF for 24 h, and
then total RNA was extracted and analyzed for the expression of Nod2
by semiquantitative RT-PCR (A) and real-time PCR (B). C, the levels of
c-IAP1, c-IAP2, and TRAIL were analyzed in MCF-7 cells following
treatment with TNF for the indicated time intervals. GAPDH mRNA
was used as an amplification control. Histograms represent the
means  S.D. of triplicate analyses.
FIG. 5. Transcriptional activation of the Nod2 promoter. A,
HEK293T cells were transfected with a 527-fragment of the Nod2
promoter (Nod2pt) either alone or with a mutated form of IB (IB
DN), and a mutant Nod2 promoter (mNod2pt) (mutation shown in
panel B), in the presence of a -galactosidase reporter vector
(pEF1BOS--gal). Cells were induced with TNF for 6 h or left un-
treated. C, HEK293T cells were co-transfected with the indicated tran-
scription factors, a 3-kb fragment of the Nod2 promoter, and pEF1BOS-
-gal. 24 h posttransfection, Nod2 promoter-dependent transcription
was determined. Units of luciferase activity were normalized based on
values of pEF1BOS--gal activity to control for transfection efficiency.
Data are presented as the mean of triplicate cultures  S.D. D, FHC
and HL-60 cells were stimulated with TNF or LPS for 60 min in the
presence () or in the absence () of Bay11–7082, an inhibitor of NFB
activation. Electrophoretic mobility shift assay was performed using a
radiolabeled probe from the Nod2 promoter. Nuclear extracts from
stimulated cells were preincubated with antibodies specific for p50
and p65.
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sponses. Interestingly, some of the target genes of NF-B (IL-
1, TNF), in turn activate NF-B (23). Based on these
observations, we first analyzed the expression of Nod2 mRNA
in myeloblastic HL-60 cells after treatment with two NF-B
activators, LPS and TNF. Nod2 was weakly expressed in
unstimulated HL-60 cells, but after treatment for 24 h with
either LPS or TNF, the mRNA levels of Nod2 increased about
8- and 70-fold, respectively (Fig. 3, A and B). This expression
pattern was similar to that of the IL-1 gene (Fig. 3A), a known
target of NF-B. We then analyzed whether Nod2 could also be
induced in non-hematopoietic cells. As shown in Fig. 4A, the
expression levels of Nod2 mRNA were very low in two breast
cancer cell lines, SUM159 and MCF-7, and in FHC (an epithe-
lial cell line derived from normal colon). By 24 h of stimulation
with TNF, the levels of Nod2 mRNA in SUM159 and MCF-7
were increased about 1.5- and 6-fold respectively (Fig. 4, A and
B). Up-regulation of Nod2 mRNA levels was more prominent
(23-fold) in FHC colon cells (Fig. 4B). In control experiments,
the levels of NF-B-regulated genes such as TRAIL and mem-
bers of the inhibitor of apoptosis family (c-IAP1, and c-IAP2)
were increased after treatment with TNF (Fig. 4C).
The Promoter Region of Nod2 Contains a NF-B-Consensus
Sequence That Is Responsive to TNF and LPS—Based on the
up-regulation of Nod2 in response to NF-B activators, we
searched for consensus sites within the Nod2 promoter region
and found a putative NF-B recognition sequence 121 bases
upstream from the initiation codon (Fig. 5B). To assess the
transcriptional activity of the Nod2 promoter, a 527-bp frag-
ment containing the NF-B consensus site of the Nod2 pro-
moter (Nod2pt) was cloned into a promoterless luciferase vector
(Nod2pt-luciferase), and this construct was transiently trans-
fected into HEK293T cells. Stimulation of the cells with TNF
induced the transcriptional activity about 5-fold when com-
pared with unstimulated cells (Fig. 5A). To assess the rele-
vance of the putative NF-B site, we mutated an essential base
within this sequence motif (Fig. 5B) in the Nod2 promoter
fragment. In contrast to the wild-type promoter, there were no
significant differences between TNF-stimulated and unstimu-
lated cells when the mutant Nod2-luciferase construct was
transfected into HEK293T cells (Fig. 5A). Moreover, activation
of the Nod2 promoter was dependent on endogenous NF-B, as
demonstrated by the ability of an IB dominant negative
mutant to block transactivation of the Nod2 promoter induced
by TNF (Fig. 5A). We then tested whether other transcrip-
tional factors could transactivate the Nod2 promoter using a
3-kb fragment of the promoter in a luciferase reporter con-
struct. Overexpression of the p65 subunit of NF-B induced the
activity of the Nod2 promoter about 1000-fold, whereas expres-
sion of NF-IL6, cAMP-response element-binding protein, Elk,
NF-AT4, CIITA, NF-IL3, p53, c-Myc, IRF-7, or GATA-1 in-
duced very little or no transactivation (Fig. 5C). Based on these
data, we tested if NF-B binds to the Nod2 promoter in re-
sponse to TNF and LPS by using an electrophoretic mobility
shift assay. Treatment of colon FHC cells with TNF or mye-
loid HL-60 cells with either TNF or LPS resulted in signifi-
cant increase of the NF-B-DNA complex (Fig. 5D), which was
inhibited by treatment with Bay11–7082, an inhibitor of NF-B
activation. Furthermore, the induced DNA binding complex
was shifted by incubation of the nuclear extracts with anti-p50
or -p65 antibody, indicating that the protein-DNA complex
contained NF-B (Fig. 5D). In addition, we tested the NF-B
binding ability of the same DNA probe carrying a mutated
Nod2 promoter sequence and found no electrophoretic shift of
the radiolabeled probe.2
DISCUSSION
In the present study, we have focused on the expression and
transcriptional regulation of Nod2 in different cell populations.
Our results show that under unstimulated conditions Nod2 is
primarily expressed in myelomonocytic and dendritic cells, an
expression pattern that is similar to that described for TLR4
and TLR2 (24, 25). Surprisingly, stimulation of myelomono-
cytic cells with LPS or TNF and intestinal epithelial cells with
TNF up-regulated or induced Nod2 gene expression. Further-
more, the mechanism of Nod2 regulation involves transcrip-
tional activation of the Nod2 promoter through NF-B. Because
Nod2 activates NF-B and this response is likely to mediate the
induction of cytokines including TNF, up-regulation of Nod2
may be part of a positive regulatory loop induced through
inflammatory cytokines or bacterial components. A similar reg-
ulatory mechanism has been recently described for TLR2 (26).
Although TLR2 is expressed at very low levels in unstimulated
human epithelial cells, its expression is enhanced by bacterial
pathogens through a NF-B-dependent pathway (26). There is
mounting evidence that NF-B signaling in response to patho-
gens mediates protection of the host against invading microbes.
For example, mice deficient in RICK (a factor required for Nod2
signaling) are more susceptible to Listeria monocytogenes (27).
It is interesting to note that the expression of RICK, a kinase
that is required for Nod2 signaling, is also induced by LPS
stimulation presumably via NF-B (9). Thus, enhanced expres-
sion of Nod2 and its binding partner RICK may facilitate the
response of the host to pathogens. Intestinal epithelial cells
have evolved mechanisms to prevent inappropriate activation
of inflammatory responses in the microbe-rich environment of
the gut (28). Consistent with this, we found that unstimulated
epithelial cells from normal colon express low levels of Nod2.
However, expression of Nod2 was induced following treatment
with TNF. It will be important, therefore, to assess the ex-
pression of Nod2 in epithelial tissues characterized by in-
creased levels of proinflammatory cytokines (i.e. Crohn’s dis-
ease). Down-regulation of Nod2 in epithelial cells may
contribute to the maintenance of a state of hyporesponsiveness
toward comensal microflora, which would be beneficial to the
host. However, proinflammatory stimuli derived from entero-
pathogens or other pathogenic bacteria could activate NF-B
through several mechanisms including TLR or TNF receptor
signaling. Under these conditions, activation of NF-B could
induce the expression of Nod2, which in turn activates NF-B
establishing a positive feedback loop that may contribute to the
secretion of proinflammatory cytokines and chemokines at ep-
ithelial sites.
Current therapy for Crohn’s disease includes blockage of
TNF signaling (29). This therapy is effective in reducing active
disease in patients with Crohn’s disease but no permanent cure
has been achieved. Anti-TNF therapy could inhibit the mech-
anism of Nod2 up-regulation in monocyte/dendritic cells and
epithelial cells. This may be particularly significant in patients
in which Nod2 is functional and could contribute to the in-
creased incidence of opportunistic infections associated with
anti-TNF therapy (30). The finding that Nod2 gene can be
up-regulated by activation of NF-B in both immune-compe-
tent and epithelial cells is consistent with an emerging concept
in which a microbial-epithelial-immune circuit is important for
intestinal epithelium homeostasis (31) and mucosal defense.
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